Skip to main content

anzutresgene autoleucel

Generic: Anzutresgene Autoleucel

anzutresgene autoleucel: 1 clinical trial tracked.

anzutresgene autoleucel evidence translation

What we can confirm

1 tracked trial

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about anzutresgene autoleucel, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence0 indications · 1 study sponsors

Related indications

No linked indication is available.

Clinical Trials (1)

A Prospective, Multicenter, Open-label, Randomized, Actively Controlled, Parallel-group Phase 3 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of IMA203 Versus Investigator's Choice of Treatment in Patients With Previously Treated, Unresectable or Metastatic Cutaneous Melanoma (ACTengine® IMA203-301)

NCT06743126·Phase 3·IMTX
Recruiting

Primary endpoint: Progression-free survival assessed by BICR

InterventionalRandomizedopen360 targetStarted 2025-01Completion 2031-1050 sites · Canada, France, United StatesImmatics US, Inc.